Pfizer’s pill cuts COVID deaths and hospitalisations by 90%
pharmaphorum
NOVEMBER 5, 2021
There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.
Let's personalize your content